SREBF1 and fatty liver disease: As aberrant induction of SREBP1 in the metabolically abnormal situations, including tumor progression and aging, is reported (Guo et al., 2014; Ishizuka et al., 2020; Soyal et al., 2015), these studies will provide a clue to understand the basis of various diseases, including dyslipidemia, liver steatosis, atherosclerosis, inflammatory diseases, and cancers.